News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SENS Research Foundation Announces Keynote Speakers For 2014 Rejuvenation Biotechnology Conference



7/25/2014 9:20:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, CA--(Marketwired - July 24, 2014) - The SENS Research Foundation, a nonprofit working to research, develop and promote comprehensive regenerative medicine solutions for the diseases of aging, announced today that George Church, Harvard and MIT; Peter Diamandis, X PRIZE Foundation; and Jim O'Neill, Mithril Capital Management, will be the keynote speakers for the Rejuvenation Biotechnology Conference, taking place August 21-23, 2014 at the Hyatt Regency Santa Clara in Santa Clara, California. Conference Registration is at http://sens.org/rb2014/registration.

Tweet this: @senstweet Announces Keynote Speakers for the 2014 Rejuvenation Biotechnology Conference

The conference will gather the foremost leaders from academia, industry, investment, policy, and advocacy from multiple disease communities, and build upon the novel strategies being pioneered by the Alzheimer's and cancer communities. Participants will consider the wider potential of these strategies, evaluating the feasibility of preventative and combinatorial medicine applications to treat all aging-related diseases.

Keynote Speakers for the Rejuvenation Biotechnology Conference
George Church, Robert Winthrop Professor of Genetics, Harvard Medical School and MIT Health Sciences and Technology, will open the conference on August 21st. Church is also the Director of PersonalGenomes.org and the Director of the NIH Center for Excellence in Genomic Science. His 1984 Harvard Ph.D. included the first methods for direct genome sequencing, molecular multiplexing and barcoding. These led to the first genome sequence in 1994. His innovations have contributed to nearly all "next generation" genome sequencing methods and companies. This plus chip-based DNA synthesis and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics and synthetic biology/therapeutics. He has also pioneered new privacy, biosafety, environmental and biosecurity policies.

Peter Diamandis is Vice Chairman and Co-founder of Human Longevity Inc., Chairman and CEO of the X Prize Foundation, and the Executive Chairman of Singularity University. Dr. Diamandis is an international pioneer in the fields of innovation, incentive competitions and commercial space. He is the New York Times Bestselling author of "Abundance -- The Future Is Better Than You Think." He has won multiple awards, including the first Heinlein Laureate, the 2010 Economist "No Boundaries" Innovator of the Year Award, the 2007 Arthur C. Clarke Award, the 2006 Lindbergh Award, and the 2006 Neil Armstrong Award.

Jim O'Neill is partner and chief operating officer at Mithril, a growth fund for transformative and durable technology companies in fields such as cybersecurity, next generation finance, medical robotics, enterprise cloud services, 3D seismic technology, and data integration, visualization, and analysis. Previously, O'Neill was a managing director of Clarium, a global macro investment fund. He also ran the Thiel Foundation and co-founded the 20 Under 20 Thiel Fellowship and Breakout Labs. As the Principal Associate Deputy Secretary of Health and Human Services, O'Neill helped manage an agency whose 67,000 employees regulate more than 25 percent of the U.S. economy. His main areas of policy and program responsibility included the Food and Drug Administration, the National Institutes of Health, the Centers for Disease Control and Prevention, security, intelligence, preparedness, and health diplomacy. He also made investments in drug, vaccine, and diagnostic research on the steering committee of the $200 million Biomedical Advanced Research and Development Authority.

"These keynote speakers bring to the Rejuvenation Biotechnology Conference three very diverse perspectives -- the scientific, the investment and the business perspectives," said Mike Kope, CEO of SENS Research Foundation. "Their collective expertise in these areas, combined with our plenary panels and presentations, will be an inspiration and provide a roadmap to the creation of the rejuvenation biotechnology industry."

For more information, visit http://sens.org/RB2014.

About the SENS Research Foundation (SRF)
SENS Research Foundation is a 501(c)(3) nonprofit organization that works to research, develop and promote comprehensive regenerative medicine solutions for the diseases of aging. SENS Research Foundation is focused on a damage repair paradigm for treating the diseases of aging, which it advances through scientific research, advocacy and education. SENS Research Foundation supports research projects at its Mountain View Research Center, universities and institutes around the world with the goal of curing such age-related diseases as macular degeneration, heart disease, cancer, and Alzheimer's disease. Educating the public and training researchers to support a growing regenerative medicine field are also major endeavors of the organization that are being accomplished though advocacy campaigns and educational programs.

For more information, visit www.sens.org.


Media Contact:

Jerri Barrett
408-204-7229
jerri.barrett@sens.org



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES